The PK/PD Study of Single Dose of SHR3824 in Healthy Volunteers
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
SHR3824 is a novel inhibitor of renal sodium-glucose cotransporter 2, allows an
insulin-independent approach to improve type 2 diabetes hyperglycemia. In this single-dose
study the investigators evaluated the safety, tolerablity and PK/PD profiles of SHR3824 in
healthy subjects.